Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

I2536

Sigma-Aldrich

ICI 192605

≥98% (HPLC)

Synonym(s):

(4Z)-rel-, 4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl) hexenoic acid, 4-Hexenoic acid, 6-[(2R,4R,5S)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H23ClO5
CAS Number:
117621-64-4
Molecular Weight:
402.87
MDL number:
MFCD00673936
UNSPSC Code:
12352200
PubChem Substance ID:
329815367
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

DMSO: ≥20 mg/mL

originator

AstraZeneca

storage temp.

−20°C

SMILES string

OC(=O)CC\C=C/C[C@H]1CO[C@H](O[C@H]1c2ccccc2O)c3ccccc3Cl

InChI

1S/C22H23ClO5/c23-18-11-6-4-9-16(18)22-27-14-15(8-2-1-3-13-20(25)26)21(28-22)17-10-5-7-12-19(17)24/h1-2,4-7,9-12,15,21-22,24H,3,8,13-14H2,(H,25,26)/b2-1-/t15-,21+,22+/m0/s1

InChI key

WHUIENZXNGAHQI-YGPRPMEGSA-N

Biochem/physiol Actions

ICI 192605 is a potent thromboxane A2 receptor antagonist. It inhibits platelet aggregation and can reverse the effects of vasoconstrictors such as TXA2 or PGD2. ICI 192605 can reverse vasoconstriction induced by inhibition of NO production by L-NEMA, which leads to an increase in TXA2 release.

Features and Benefits

This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation markEnvironment
GHS07,GHS09

Signal Word

Warning

Hazard Statements

H302,H410

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

I2536-5MG:
I2536-VAR:
I2536-BULK:
I2536-25MG:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
051M4719V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J J Descombes et al.
European journal of pharmacology, 243(2), 193-199 (1993-10-19)
The goal of the present study was to characterize the role of the endothelium in the 5-hydroxytryptamine (5-HT)-induced contraction of the rat basilar artery. Rat basilar artery segments were mounted in myographs to study their isometric tension development. 5-HT caused
Z Benyó et al.
Kidney international. Supplement, 67, S218-S220 (1998-09-15)
This study investigated the role of thromboxane A2 (TXA2) and neuronal nitric oxide (NO) synthase (nNOS)-derived NO in the maintenance of resting cerebrovascular tone. Rat basilar artery (BA) segments were mounted in myographs to study their isometric tension development. 7-Nitro
N al Jarad et al.
British journal of clinical pharmacology, 37(1), 97-100 (1994-01-01)
Many prostanoids including are prostaglandin (PG) F2 alpha and PGD2 are potent bronchoconstrictor agents. There is evidence to suggest that airway thromboxane (TP) receptor may act as a common receptor for their bronchoconstrictor actions. We tested the hypothesis that inhaled
S M Hutchinson et al.
Journal of lipid mediators and cell signalling, 15(3), 249-254 (1997-03-01)
A number of eicosanoids caused plasma membrane blebbing in hepatocytes and this could be inhibited in a dose-dependent fashion by the receptor antagonists AH6809 and ICI 192605. The pattern of effectiveness of eicosanoids interfering with canalicular vacuole accumulation in hepatocyte
Z Benyó et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 18(6), 616-618 (1998-06-17)
Inhibition of nitric oxide (NO) synthesis induces vasoconstriction and reduction of the blood flow in the brain, indicating that basal release of NO provides a resting vasorelaxant tone in the cerebral circulation. In the present study, the contractile effect of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service